Hospira likely to face FDA enforcement action, says RBC Capital RBC Capital said its review of the latest Form 483 for Hospira's Rocky Mount facility reinforces the firm's belief that the FDA will enter into a consent decree with the company.
News For HSP From The Last 14 Days
Check below for free stories on HSP the last two weeks.
Cubist options active on speculation of a favorable patent ruling Cubist (CBST) June 55 calls and June 47 puts are active on total call volume of 3K contracts (3K puts). June call option implied volatility is at 37, August is at 40; compared to its 26-week average of 36 according to Track Data. Active option volume suggests traders taking positions for movement on speculation of a favorable patent ruling vs.Hospira (HSP).
Hospira reappoints Dr. Sumant Ramachandra to Chief Scientific Officer Ramachandra has been reappointed to his role as Senior VP and Chief Scientific Officer effective May 17. Ramachandra returns to Hospira after a brief departure earlier this year.
Subscribe for More Information
